VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, a breakthrough that the company claims can isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This development addresses a long-standing challenge in liquid biopsy: separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. By creating highly enriched tumor DNA datasets, the technology could significantly improve cancer detection and monitoring.
The study describes a two-step process that combines physical sample enrichment with bioinformatic filtering to achieve ctDNA purity exceeding 99%. Early validation studies have shown strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have also produced encouraging findings, according to the company.
The implications of this technology are substantial. Volition estimates that the annual market opportunity for multi-cancer early detection is approximately $23 billion, while minimal residual disease applications represent more than $13 billion. These figures underscore the potential impact on the healthcare industry, where early detection is critical for improving patient outcomes and reducing mortality rates.
Liquid biopsy, a non-invasive alternative to traditional tissue biopsies, has been a focus of cancer research for years. However, the difficulty of isolating ctDNA from the vast amount of normal DNA has limited its clinical utility. Volition's Capture-Seq technology appears to overcome this hurdle, offering a more reliable and accurate method for detecting cancer at earlier stages when treatment is most effective.
The company is now advancing larger validation studies and working with oncology key opinion leaders to further validate the technology. It is also expanding its patent protection as it explores commercialization opportunities, including technical evaluations with potential licensing partners.
This publication marks a significant milestone for Volition, which is known for its work in epigenetics. The company focuses on developing simple, cost-effective blood tests for a range of diseases, including cancer and sepsis. With this new technology, Volition could play a pivotal role in transforming cancer diagnostics, potentially leading to earlier detection and better patient outcomes.
The peer-reviewed publication adds scientific credibility to the technology, which is crucial for adoption in the medical community. As Volition continues to validate and refine its approach, the potential for this technology to become a standard tool in oncology is high.
For more information, see the full press release at https://ibn.fm/nuJEs.
